⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Supplementary Figure S3 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma

Paolo Strati Lei Feng Andrey Tyshevich Darya Shavronskaya Julia Alesse Noel English Elizabeth Sheehan Nikita Syzrantsev Alexander Nesmelov Tony Zhuang Dai Chihara Jason R. Westin Sairah Ahmed Luis Fayad Jared Henderson Karin M. Dent Elizabeth McChesney Sattva S. Neelapu Christopher R. Flowers

View Full Paper

Ask AI

Bookmark

Share

Key Points

The trial explores the efficacy of evorpacept along with lenalidomide and rituximab for lymphoma treatment.
Key findings include notable associations between cytokine changes and patient progression in lymphoma cases.
This phase I trial involved direct monitoring of cytokine variability in patients, revealing critical patterns.
Results indicate potential modifications in therapy approaches based on cytokine responsiveness during treatment.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Phase I trial evaluates cytokine changes related to lymphoma progression, suggesting novel treatment insights.

Abstract

Associations between cytokine changes and progression

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Strati et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21a44 https://doi.org/10.1158/1078-0432.30255116

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure S2 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
2Supplementary Figure S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
3Supplementary Figure S4 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
4Data from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025
5Supplementary Protocol S1 from A Phase I Trial of Evorpacept, Lenalidomide, and Rituximab for Patients with B-Cell Non-Hodgkin Lymphoma2025